Anticholinergic drugs for parkinsonism and other movement disorders
Recommended Citation
LeWitt PA, Hong L, and Moehle MS. Anticholinergic drugs for parkinsonism and other movement disorders. J Neural Transm (Vienna) 2024.
Document Type
Article
Publication Date
6-21-2024
Publication Title
J Neural Transm (Vienna)
Abstract
Anticholinergic (AC) drugs, a medication class that acts by blocking nicotinic and muscarinic acetylcholine receptors, were first utilized for therapeutic purposes in the mid-19th century. Initial applications were as symptomatic therapy for Parkinson disease (PD), a practice continuing to the present. Initially, the AC drugs used were naturally-occurring plant compounds. Synthetic AC drugs were developed in the late 1940s and predominated in neurological therapeutics. Until the advent of pharmaceuticals acting upon striatal dopaminergic motor pathways, AC drugs provided the only effective means for lessening tremors and other clinical problems of the PD patient. However, because dopaminergic compounds are so effective at meeting the needs of the typical PD patient, AC medications are far less utilized by clinicians today. In recent years, there has been only a few investigations of AC drugs as neurological treatments. This review will revisit the clinical landscape of AC pharmacology and application for movement disorders along with recent research in search of improving therapeutics with AC drugs.
PubMed ID
38904792
ePublication
ePub ahead of print
